BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24761409)

  • 1. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer.
    Lee MY; Park JH; Bae KS; Jee YG; Ko AN; Han YJ; Shin JY; Lim JS; Chung CH; Kang SJ
    Ann Surg Treat Res; 2014 Feb; 86(2):55-60. PubMed ID: 24761409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
    Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
    Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
    Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
    J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.
    Kim CW; Hong S; Oh SH; Lee JJ; Han JY; Hong S; Kim SH; Nam M; Kim YS
    J Bone Metab; 2015 Aug; 22(3):135-41. PubMed ID: 26389089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
    Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
    J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation.
    Leonova TA; Drozd VM; Saenko VA; Mine M; Biko J; Rogounovitch TI; Takamura N; Reiners C; Yamashita S
    Endocr J; 2015; 62(2):173-82. PubMed ID: 25374130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
    Bin-Hong D; Fu-Man D; Yu L; Xu-Ping W; Bing-Feng B
    Endokrynol Pol; 2020; 71(1):15-20. PubMed ID: 31681976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.
    Jódar E; Martínez-Díaz-Guerra G; Azriel S; Hawkins F
    Calcif Tissue Int; 2001 Aug; 69(2):84-7. PubMed ID: 11683428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma.
    Zanella AB; Marmitt L; Fighera TM; Scheffel RS; Spritzer PM; Dora JM; Maia AL
    Metabolites; 2022 Sep; 12(9):. PubMed ID: 36144246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Bone Mineral Density Using DXA and cQCT in Postmenopausal Patients Under Thyrotropin Suppressive Therapy.
    Kim K; Kim IJ; Pak K; Kim SJ; Shin S; Kim BH; Kim SS; Lee BJ; Jeon YK
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4232-4240. PubMed ID: 29982711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.